Intersect ENT

Intersect ENT Inc. (formerly Sinexus) is a medical device company pioneering novel therapies for Ear, Nose, and Throat surgeons to utilize in providing improved treatment for their patients. The company was founded in 2003 by Don Eaton and is headquartered in Menlo Park, California, United States.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference

Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference

Intersect ENT, Inc. (XENT) CEO Tom West on Q4 2020 Results - Earnings Call Transcript

Intersect ENT (XENT) delivered earnings and revenue surprises of -74.19% and 1.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Reports Q4 Loss, Tops Revenue Estimates

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Fourth Quarter 2020 Financial Results

Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid Services (CMS) published an average selling price (ASP) for the Company's SINUVA sinus implant, providing predictability, transparency, and confidence of reimbursement for providers and payers going forward. In January 2021, CMS created separate and distinct cod

CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication

Intersect ENT (XENT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Intersect ENT (XENT)

Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results

Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results

Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.

Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company's PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received premarket approval (“PMA”) by the U.S. Food and Drug Administration (“FDA”) which follows PMA for the

Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Participate in Upcoming Investor Conferences

Intersect ENT to Participate in Upcoming Investor Conferences

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant

Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant

Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.

Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020

Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

CORRECTING and REPLACING - Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.

Intersect ENT (XENT) Banks on SINUVA Sales Amid COVID-19 Woes

Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?

Intersect ENT (XENT) Up 17.6% Since Last Earnings Report: Can It Continue?

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces New Appointments to Executive Leadership Team

Intersect ENT Announces New Appointments to Executive Leadership Team

Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.

Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates

Intersect ENT, Inc.'s (XENT) CEO Tom West on Q3 2020 Results - Earnings Call Transcript

Intersect ENT (XENT) delivered earnings and revenue surprises of 22.73% and 0.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Intersect ENT (XENT) Reports Q3 Loss, Tops Revenue Estimates

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Third Quarter 2020 Financial Results

Intersect ENT Reports Third Quarter 2020 Financial Results

Intersect ENT (XENT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.

News for Intersect ENT Stock (XENT)